Pas de connexion internet — affichage de la version enregistrée de la page.

Bristol-Myers Squ…

USUSD
← Vers le Screener

Bristol-Myers Squibb Company (XETRA:BRM) — Drug Manufacturers - General. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 6. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
bms.com
Relations avec les Investisseurs
bms.com/investors.html
Secteur
Healthcare · Drug Manufacturers - General
Siège Social
PRINCETON, United States
PDG
Christopher S. Boerner
Employés
32 500
Fondée
1989
Actions en Circulation
2.04 Md au 2026-07-22
Flottant
2.04 Md
Capitalisation Boursière
128.41 Md USD
Initiés
0.1%
Investisseurs Institutionnels
84.87%
Secteur d'Activité (SIC)
Pharmaceutical Preparations
Forme Juridique
XTIQ
ISIN
US1101221083
LEI
HLYYNH7UQUORYSJQCN42
P/E
13.8
Taux de Distribution
54.9%
FCF
11.4 Md USD
Versements / FCF
45%
Dette
43.9 Md USD
3.1 ans de FCF
Ancienneté du Dividende
54 ans
Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
NAV
10.93 USD · P/NAV 5.53
Date du Bilan30.06.2026
Actifs87.6 Md USD
− Passifs65.3 Md USD
= NAV (capitaux propres des actionnaires de la société)22.3 Md USD
− Écart d'Acquisition (Goodwill)21.7 Md USD
− Actifs Incorporels17.4 Md USD
= NAV Tangible−16.8 Md USD
Actions2 042 714 656
NAV par Action10.93 USD
VLV Tangible par Action−8.23 USD
Prix de l'Action (BRM)53.0400 EUR
P/NAV5.53
Historique de la NAV
Date du BilanNAVNAV par Action
30.06.202622.3 Md USD10.93 USD
31.03.202620.1 Md USD9.83 USD
31.12.202518.5 Md USD9.07 USD
30.09.202518.6 Md USD9.11 USD
30.06.202517.4 Md USD8.57 USD
31.03.202517.4 Md USD8.54 USD
31.12.202416.3 Md USD8.05 USD
30.09.202417.1 Md USD8.45 USD
Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksBMY principaleUSD60.57 +2.18%actions ordinaires
LSE London Stock Exchange0R1F IOBGBP—actions ordinaires
MI Borsa Italiana (Milan)1BMY secondaireEUR54.3 -1.08%actions ordinaires
MX Mexican Stock ExchangeBMY secondaireMXN1 130 +7.93%actions ordinaires
VI Vienna Stock ExchangeBMYS secondaireEUR52.98 +0.34%actions ordinaires
XETRA XetraBRM secondaireEUR53.04 +0.89%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Par an, US:BMY: 2.52 USD (4 vers.)

Bristol-Myers Squibb Company (BMY) verse des dividendes trimestriels. Par an (12 mois jusqu'au dernier paiement annoncé inclus) : 2.52 USD par action (paiements : 4). Cela représente environ 4.16% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 01.01.2027. Historique des dividendes ininterrompu : 54 ans.

Date ExVersementMontant%TypeTicker
2026-10-022026-11-020.6300 USD1.0/4.1 %trimestrielUS:BMY
2026-07-022026-08-030.6300 USD1.1/4.4 %trimestrielUS:BMY
2026-04-022026-05-010.6300 USD1.0/4.0 %trimestrielUS:BMY
2026-01-022026-02-020.6300 USD1.2/4.6 %trimestrielUS:BMY
2025-10-032025-11-030.6200 USD1.4/5.4 %trimestrielUS:BMY
2025-07-032025-08-010.6200 USD1.3/5.2 %trimestrielUS:BMY
2025-04-042025-05-010.6200 USD1.1/4.2 %trimestrielUS:BMY
2025-01-032025-02-030.6200 USD1.1/4.3 %trimestrielUS:BMY
2024-10-042024-11-010.6000 USD1.0/4.0 %trimestrielUS:BMY
2024-07-052024-08-010.6000 USD1.0/3.9 %trimestrielUS:BMY
2024-04-042024-05-010.6000 USD1.0/3.9 %trimestrielUS:BMY
2024-01-042024-02-010.6000 USD1.0/3.8 %trimestrielUS:BMY
2023-10-052023-11-010.5700 USD0.9/3.8 %trimestrielUS:BMY
2023-07-062023-08-010.5700 USD0.9/3.7 %trimestrielUS:BMY
2023-04-062023-05-010.5700 USD0.9/3.7 %trimestrielUS:BMY
2023-01-052023-02-010.5700 USD0.9/3.6 %trimestrielUS:BMY
2022-10-062022-11-010.5400 USD0.9/3.6 %trimestrielUS:BMY
2022-06-302022-08-010.5400 USD0.9/2.7 %trimestrielUS:BMY
2022-03-312022-05-020.5400 USD0.9/1.8 %trimestrielUS:BMY
2022-01-062022-02-010.5400 USD0.9/0.9 %trimestrielUS:BMY

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Blackrock Inc.8.83%180.38 M2026-06-30
Vanguard Capital Managem…6.53%133.34 M2026-06-30
State Street Corporation5.01%102.41 M2026-06-30
JPMORGAN CHASE & CO3.51%71.71 M2026-06-30
Charles Schwab Investmen…3.31%67.6 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%64.83 M2026-06-30
Geode Capital Management…2.76%56.44 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%52.92 M2026-06-30
SCHWAB STRATEGIC TRUST-S…2.38%48.64 M2026-05-31
Vanguard Portfolio Manag…2.29%46.87 M2026-06-30
NORGES BANK1.8%36.87 M2026-06-30
Bank of America Corporat…1.67%34.05 M2026-06-30
Price (T.Rowe) Associate…1.55%31.71 M2026-06-30
iShares Trust-iShares Co…1.35%27.55 M2026-08-31
Fidelity Concord Street…1.29%26.41 M2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%24.96 M2026-08-31
VANGUARD INDEX FUNDS-Van…0.95%19.44 M2026-06-30
SELECT SECTOR SPDR TRT-S…0.72%14.68 M2026-08-31
VANGUARD CHESTER FUNDS-V…0.7%14.29 M2026-06-30
VANGUARD INSTITUTIONAL I…0.54%11.09 M2026-06-30
LEUNG SANDRA (General Co…≈0.02%465 3742025-03-10
ELKINS DAVID VINCENT (Ch…≈0.01%159 5422026-04-01
BOERNER CHRISTOPHER S (C…≈0.01%146 8902026-03-10
HIRAWAT SAMIT (Officer)≈0%83 5132025-04-25
HALLER JULIA A (Director…≈0%34 0792026-06-15
MEYERS GREGORY SCOTT (Ch…≈0%30 3612026-03-10
LENKOWSKY ADAM (Officer)≈0%28 6772026-05-01
SHANAHAN KARIN (Officer)≈0%27 3452026-04-01
PLENGE ROBERT M (Officer…≈0%24 7542026-03-10
MASSACESI CRISTIAN (Offi…≈0%18 7482026-09-09